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PURPOSE: Multiple Sclerosis (MS) is a chronic condition managed by disease modifying
pharmaceutical therapies (DMTs). Health care cost is increasing due to high prescription drug
spending. The high cost of branded DMTs highlights the potential value of lower cost generic
therapies. Using generic DMTs could reduce the spending in the prescription drug sector.
Recently, generic glatiramer acetate (GA) that treats relapsing remitting multiple sclerosis has
become available. Appropriate insurer policies and practices are imperative to promote the use
and utilization of generics like GA. Notably, no study has specifically evaluated the differences in
utilization uptake of branded vs generic GA among the major insurer categories. The purpose of
this study is to establish whether i n s u r e r type affects the rate of utilization uptake of branded
vs generic GA.
METHODS: Prescription claims data for branded or generic glatiramer acetate for
Commercially insured patients, Medicare beneficiaries with supplemental insurance, and
Medicaid patients were extracted from Symphony Health Integrated Dataverse® data set from
Oct 2014 – Jan 2019. Patient claim cohorts were identified through branded Copaxone® 20 mg
or 40 mg, generic Glatopa® 20 mg or 40 mg, and generic Mylan Glatiramer Acetate 20 mg or 40
mg national drug codes. Data was limited to 52 months of claims data inclusive of FDA postapproval of generic glatiramer acetate options. Projected glatiramer acetate utilization rates were
estimated using exponential regression modeling. Patient out of pocket costs were captured as
pharmacy transactional level insights from the patient’s primary plan pay setting of the initial copay amount and additional plan pay from third-party utilization of copay cards subsidizing the
prescription.
RESULTS: From October 2014 to January 2019, 111,906 patients with multiple sclerosis were
prescribed glatiramer acetate by Neurologists (80%) and had 1,624,159 approved dispensed
claims primarily through specialty mail (87%) and categorized by payment type as 63.2%
Commercial, 25.4% Medicare, and 11.8% Medicaid. The market trend showed a consistent
decline in branded glatiramer acetate claims offset by a rapid uptake in generic glatiramer acetate
with its initial market entry but remained relatively flat until launch of an additional generic
market entrant. Generic market share has continued to grow reaching an approximate 30% share
of claims. Over the 52 months brand glatiramer acetate utilization has declined more than half at
56%, while generic claim volume has grown 155% over the past 16 months. Among the payer
types, Medicare has observed the greatest brand decline at 70% and the second highest generic
utilization uptake at a 28% share. Commercial insurers have the greatest category claim volume
and greatest generic growth to a 26% share, while the brand has declined by 44%. Medicaid has
had the lowest utilization volume and the greatest ratio of generic utilization among insurers at
45%. Patient out of pocket costs are highest with branded use across all insurer types, while
Medicaid has the lowest patient out-of-pocket costs. Across all payment types, generics offer
approximately a 20% discount to the brand in patient out of pocket costs.
CONCLUSION: The study revealed that generic glatiramer acetate adoption or utilization has
been slow among insurers but increasing over the past sixteen months with additional generic
GA entrants and increased price competition. The greatest trend in generic utilization is
occurring within the Commercial channel followed by Medicare and Medicaid, which has had the
lowest growth trend. The results indicate that barriers to generic glatiramer acetate may vary by
insurer and influenced by prescriber or patient choice. Generic uptake is projected to increase
across all insurer types reflective of trends during 2019 open enrollment and healthcare benefit
design change associated with a new health insurance cycle. Lower patient out-of-pocket costs
viii

and generic preferred formulary positioning will influence utilization rates, especially in
beneficiaries or enrollees with the greatest financial cost shift risk.
KEYWORDS: Benefit Design, Copaxone®, Drug Utilization, Formulary Management, Generic,
Glatiramer Acetate, Multiple Sclerosis, DHA, Doctor of Health Administration.
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CHAPTER 1
INTRODUCTION

Background of Glatiramer Acetate and Need for Analysis
Multiple sclerosis (MS) is a chronic, autoimmune, neurological disease affecting the
central nervous system caused by the demyelinating of neurons, which results in an inability of
nerve cells to transmit signals and producing a wide variety of symptoms (Freedman, Selchen,
Prat, & Giacomini, 2018). MS affects approximately 1 million people in the US (Wallin, 2019).
Multiple sclerosis is associated with progressive disability, reductions in quality of life, and is a
tremendous economic burden for patients, families, and society (Naci, Fleurence, & Birt, 2010).
It has been reported that total all-cause health care costs associated with MS including direct and
indirect costs in the United States ranged from $8,528 to $52,244 per patient per year (Adelman,
Rane, & Villa, 2013).
In the absence of a cure, MS therapy consists primarily of supportive care and
symptomatic management, which may generate substantial direct costs. A mainstay for treatment
is disease-modifying therapies (DMTs) or medications that alter immune response. With
appropriate use of these DMTs, significant clinical benefit may be realized by slowing
progression or altering the course of various forms of the disease. DMTs are considered specialty
pharmaceuticals, a category associated with insurance restrictions like prior authorization, step
therapy, formulary tiers and co-insurance due to their high cost, complexity of the disease they
treat, and the need for enhanced clinical services to ensure safe use of the drug and to optimize
therapeutic outcomes (Penington & Stubbings, 2016). Amongst these DMTs, Copaxone® or
glatiramer acetate stands out due to its unique mechanism of action and demonstrated extensive
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clinical experience supporting its efficacy, safety, and generally good patient tolerability
(Caporro, Disanto, Gobbi, & Zecca).
Copaxone® has also been recognized as the DMT with the highest cost increases at
greater than 1000%, which far exceeds standard prescription inflation rates. Branded Copaxone®
initial cost when launched in 1996 was $9,000 a year and now has increased to over $85,000 a
year contributing to higher cumulative direct healthcare costs (Hartung, Bourdette, Ahmed, &
Whitham, 2015). In fact, recent research has found that most MS DMTs have increased in
acquisitions cost to approximately $80,000 per patient per year (Hartung, Johnston, & Bourdette,
2018). The research confirms that the cost to treat MS with DMTs is extremely high. By itself,
MS ranked eighth by drug invoice spending among the top therapeutic classes in the U.S. in
2016, representing nearly $19 billion in drug spending alone (IQVIA, 2017). The introduction of
these expensive specialty DMTs for the treatment of MS has created the potential for patients
with MS to become higher contributors to healthcare spending (Anderson & Philbrick, 2014).
Specialty drugs have become a major driver of prescription drug costs for insurers as well as outof-pocket expenses borne by the patient. Since about half of specialty drug spending is on selfadministered agents covered under the pharmacy benefits, these have been the focus of payer
efforts to control spending. Insurers and pharmacy benefit managers seeking to manage costs
have largely been unable to use the traditional 3-tiered cost-sharing design to encourage
utilization of lower-cost drugs since specialty drugs often have few close, less-expensive
substitutes until recently.
The primary patent for Teva’s brand Copaxone® (glatiramer acetate) 20 mg daily ended
in May 2014. Its expiration or invalidation of remaining patents created the opportunity to
develop generic alternatives, which could result in cost savings for patients and payers.
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Following submission of an ANDA in December 2007, the first generic glatiramer acetate named
GLATOPA® was approved by the FDA in April 2015, based on demonstration of equivalent
physicochemical characteristics plus immunologic and clinical effects to Copaxone®.
Subsequently, the Glatopa® 40 mg generic formulation was approved in February 2018. In
parallel, Mylan Pharmaceuticals received approval of its 20 and 40 mg generic versions of
glatiramer acetate in October 2017. Both generic versions were introduced at wholesale
acquisition cost discounts of between 15 to 70% discount to branded Copaxone®. Generic drugs
are one of the most effective checks on rising drug costs in the United States (Kohl & Shrank,
2007). Thus, the current MS treatment landscape may change with the approval of less expensive
generic versions of DMTs for MS.
Reducing the cost of MS DMTs would have a significant impact on the cost-effectiveness
of these drugs and patient costs (Owens, 2016). With increased availability and development of
less expensive generic specialty pharmaceuticals, US insurers can implement appropriate
prescription management strategies to control both overall utilization and costs within the MS
category if they should choose. Key insurer management strategies for specialty pharmaceuticals
could include the implementation of specialty tiers and complex formulary designs, drug
restrictions through prior authorizations and quantity limits, co-payments and co-insurance rates
that increase patient cost burden, and government regulation for pharmaceutical step-therapy
interventions and drug price controls (Patel & Audet, 2014). Moreover, insurers may implement
specialty pharmacy provider dispensing for drug distribution, medication therapy management
programs to increase coordination of care, quality measures enforced through healthcare reform
and accountable care organizations and increased use of evidence-based medicine.
Many insurers have already adopted incentive-based formularies to control prescription-
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drug costs through generic utilization in other therapeutic categories. An incentive based, or
tiered formulary provides financial incentives (i.e., lower copayments) for enrollees to choose
drugs that are preferred by the payer. Different changes in formulary administration may have
dramatically different effects on utilization and spending and may in some instances lead
enrollees to discontinue therapy. The associated changes in copayments can substantially alter
out-of-pocket spending by enrollees, the continuation of the use of medications, and possibly the
quality of care (Happe, Clark, Holliday, & Young, 2014).
Differences in benefit design between insurer types (Commercial, Medicare, and
Medicaid) and differences in patient out of pocket costs may lead to variations in the rate of
utilization uptake of generic vs branded glatiramer acetate among patients depending on the
type of insurance. Little is known regarding the impact or use of generic treatments in MS.
Insight into MS market dynamics is important as it provides an opportunity to assess
management and utilization of generic prescription medications in MS through insurance
benefit design.
Problem Statement
This study investigates the utilization uptake of generic vs. branded glatiramer acetate in
multiple sclerosis (MS) using prescription claims data to highlight any differences in uptake
between the three primary insurance payer types through benefit coverage and design. The
primary insurance types include Commercially insured, Medicare, and Medicaid payers. This is
an important area of research because there are no studies examining current utilization
incentives used by insurers to facilitate generic glatiramer acetate uptake as covered
beneficiaries. Literature articles indicate that MS imposes a significant economic burden on
patients and the US healthcare system utilization. MS prescription drug costs have risen in a
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dramatic fashion. The cost of MS drugs in the United States is rising five to seven times faster
than the normal rate of drug inflation (Hartung, Bourdette, Ahmed, & Whitham, 2015).
Therefore, insurers have introduced multiple formulary reforms and initiatives to optimize the
managed entry of new drugs, in addition, to help control expenditure of existing drugs through
the encouraged use of prescription generics leveraging lower cost and increased competition.
Increased utilization of generic MS drugs my increase treatment access and help in controlling
costs.

5

Research Question
Does generic glatiramer acetate availability lead to greater utilization among insurers in
treatment of multiple sclerosis?

Population
This is an archival data analysis of U.S. patients with multiple sclerosis that are
Commercially insured, Medicare, and Medicaid beneficiary cohorts identified by branded or
generic 20 mg or 40 mg glatiramer acetate utilization analyzed through de-identified claims data
licensed from Symphony Health for a 52-month period from October 1, 2014 to January 31,
2019.
Assumptions
Increasing healthcare expenditure has led healthcare authorities, providers, and patients to
minimize costs and maximize savings relative to outcomes (Burke & Ryan, 2014). Brand
medication cost is a key component from both an affordability and accessibility perspective
(National Academies of Sciences, Engineering, and Medicine, 2017). Upon patent loss by the
originator of a branded drug, generic drug entry is soon to follow pending FDA approval. The
FDA has approved two generic forms of glatiramer acetate on the basis that they are bioequivalent
to the brand. Generic drugs are usually priced at a discount to the originator and thus offer direct
acquisition cost savings to the payer and patient savings in the form of lower copayments (Landon
et al., 2007). Switching from branded to generic medication use is a common cost containment
measure. Drug insurance plans typically encourage preferred vs non-preferred drug use through
tiered pharmaceutical formularies to guide prescription-drug use, requiring relatively small patient
copayments for inexpensive generic drugs and higher copayments for brand-name drugs
(Kouvelis, Xiao, & Yang, 2015).
Pharmaceutical manufacturers, however, use coupons to reimburse patients for this
6

difference in copayments when they buy brand-name medications, so that, for people with
commercial insurance coverage, the out of pocket costs are the same as those for generic drugs.
Patients with commercial insurance like the coupons because they can help make expensive
brand-name drugs more affordable. But the coupons may also discourage patients from
considering appropriate lower-cost alternatives, including generics. It is however illegal under
the federal anti-kickback law for drug manufacturers to offer any type of payment that might
persuade a patient to purchase something that federal health care programs like Medicare and
Medicaid might reimburse. Pharmaceutical manufacturers may sponsor patient assistance
programs (PAPs) that provide financial assistance or drug free product (through in-kind product
donations) to low income individuals to augment any existing prescription drug coverage. PAPs
also can aid Part D enrollees and interface with Part D plans by operating "outside the Part D
benefit" to ensure separateness of Part D benefits and PAP assistance. Theses Medicare Savings
or Extra Help Programs can help pay for patient premiums and out-of-pocket costs, such as
deductibles and coinsurance. Medicare currently identifies products costing over $670 per month
as specialty tier products allowing to charge between 25 percent and 33 percent coinsurance for
specialty tier drugs to enrollees. In addition, unlike commercial plans that cap members' out-ofpocket drug spending annually, Medicare has no limit for prescription medications in Part D, its
prescription drug benefit.
As a result, Commercial patients may be shielded from cost-sharing initiatives, thus
undermining Commercial insurers’ ability to influence generic drug utilization as may be found
within Medicare and Medicaid beneficiaries. In addition, insurance providers with higher
utilization uptake of generic glatiramer acetate occurs when initiatives to reduce prescribing
costs drive use of MS generics by placing more restrictions on branded products compared to
payers with less initiatives.
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CHAPTER 2
LITERATURE
REVIEW

Overview
A literature review was conducted to expand on the background and unmet need for this
study by analyzing previous research or available studies relating to my research question to assess
any important findings to build on a theoretical foundation of knowledge and find applicable
relevance in those insights. The primary objective of this literature review was to explore brand vs
generic drug utilization trends in the treatment of multiple sclerosis and to gain an understanding
on an optimal study design to approach research question.
MS and Disease Modifying Therapies
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central
nervous system (CNS) (Reich, Lucchinetti, & Calabresi, 2018). It is characterized by demyelination
of axons (Figure 1) in the brain and spinal cord with axonal damage or destruction (English & Aloi,
2015). MS affects predominately patients aged 20-50 years with women affected twice as often as
men (Gooch, Pracht, & Borenstein, 2017). The exact etiology is unknown and likely results from
complex interactions of both environmental and genetic factors. The symptoms of MS vary
depending in part on the location of lesions within the central nervous system. Common symptoms
include sensory disturbances in the limbs, optic nerve dysfunction, pyramidal tract dysfunction,
bladder or bowel dysfunction, sexual dysfunction, ataxia, and diplopia (Noyes & WeinstockGuttman, 2013). Although there is large variability in symptom manifestation and disease
progression, MS is still the most common cause of non- traumatic disability in young adults and is
associated with an average reduction in life span of 5 to 10 years (English & Aloi, 2015). Current
8

MS classification is based upon different defined clinical courses and consensus on the nature of
the disease. The first is relapsing-remitting MS (RRMS), which is characterized by interspersed
self-limited clinical events known as “relapses” or “attacks” of neurologic dysfunction with periods
of clinical remission without disease progression in approximately 85% of patients (Weinshenker,
1994). The second clinical course is secondary progressive MS (SPMS), which is comprised of
about two-thirds of RRMS patients that progress in worsening neurological function due to
accumulating axonal damage over years of active disease with or without attacks (Lublin, Reingold,
& Cohen, et al).The third clinical type is primary progressive MS (PPMS), which is characterized
by a continued steady decline in neurological function in about 10-15% patients from the first onset
of a new attack or recurrent symptoms without any subsequent attacks (Koch, Kingwell,
Rieckmann, & Tremlett). The fourth type is progressive–relapsing MS (PRMS), which also begins
with a progressive course except patients do experience at least one occasional attack over a longer
time period (Goodin, Frohman, & Garmany, et al, 2002).
Figure 1: Axonal Damage Consequent to Demyelination. One of the potential mechanisms
accountable for axonal loss following demyelination is Wallerian degeneration, whereby axons
degenerate distal to the site of damage resulting in function loss or downstream effect including
decreased levels of the neuronal marker N-acetyl aspartate (Lisak, 2007).

There are no single clinical feature, laboratory test, or imaging findings that is enough to
9

diagnose that a person has MS. The diagnosis ultimately is a clinical decision based on weighing
the factors that support the diagnosis against those that fail to support it or point to the possibility
of an alternative diagnosis. The International Panel on MS Diagnosis criteria, also called the
McDonald criteria, has set new diagnostic criteria for MS that incorporate the clinical characteristics
and MRI features of CNS lesion “dissemination in space” (DIS – suggestions of damage in more
than one place in the nervous system) and “dissemination in time” (DIT – suggestions that damage
has occurred more than once) to speed the diagnostic process and reduce the chance of
misdiagnosis thereby delaying treatment to limit permanent damage (Thompson, Banwell, &
Barkhof, et al, 2018).
Even though MS is not a curable disease, drug treatment options are available to reduce
frequency of attacks, manage symptoms, and slowing down disease progression by targeting the
mechanisms that underlie inflammation. The selection of MS drug treatment(s) has become very
challenging because of the number and availability of therapies including new agents with more
complex mechanisms of action and greater risks of adverse effects that may influence initial and
subsequent therapeutic choice. Patients with MS may benefit from treatment but individual
response to a given therapy and adverse events occurrence are largely unpredictable and many
cases need to change several drugs to stabilize their disease. Although much remains unknown
about the long-term effects of using or switching between disease-modifying therapies (DMTs),
factors such as presence of co-morbidities, desire for pregnancy, previous use of other
immunosuppressant’s, John Cunningham virus antibody seropositivity, geographical parameters,
health insurance coverage, and patient/neurologist preferences can influence the treatment selection
or sequence of treatment selection (Freedman, Selchen, Prat, & Giacomini, 2018). The choice of a
specific agent should be individualized according to disease activity, patient values, and
preferences. Currently, there are 17 DMTs approved by the U.S. Food and Drug Administration
10

(FDA) for the treatment of the various forms of MS as shown in Table 1.
Table 1: FDA Approved Multiple Sclerosis Disease Modifying Therapies (adapted from
Freedman, Selchen, Prat, & Giacomini, 2018).

Drug
Chemical Name

Brand Name
Manufacturer

Subcutaneous injection
Avonex®
Interferon β-1a
Biogen
Rebif®
EMD Serono
Plegridy®
Biogen
Betaseron®
Interferon β-1b
Bayer
Extavia®
Novartis
Copaxone®
Glatiramer
Teva
acetate (GA)
Glatopa®
Sandoz/Novartis
Generic GA
Mylan
Oral
Gilenya®
Fingolimod
Novartis

Teriflunomide

Dimethyl
fumarate
Siponimod

Cladribine

Class

FDA Approved
Dose

FDA
Approved
Indication

Interferon

30 mcg weekly

RRMS

Interferon

22 mcg or 44 mcg
three times
125 kl
mcg every 14
days
250 mcg every
other day
250 mcg every
other day
20 mg daily
40 mg three times
kl daily
20 mg
40 mg three times
kl daily
20 mg
40 mg three times

RRMS

Peginterferon
Interferon
Interferon
Synthetic mixed
polymers
Synthetic mixed
polymers
Synthetic mixed
polymers

RRMS
RRMS
RRMS
RRMS
RRMS
RRMS

0.5 mg once daily

RRMS

Aubagio®
Pyrimidine
Sanofi Genzyme synthesis
inhibitor
Tecfidera®
Multifactorial
Biogen)
Mayzent®
Sphingosine 1Novartis
phosphate receptor
modulator

7 mg or 14 mg
daily

RRMS

240 mg twice
daily
0.25 mg once
daily

RRMS

Mavenclad®
EMD Serono

10 mg tablet once
daily for 4 or 5
days two times
per year

RRMS
SPMS

Sphingosine 1phosphate
receptor
modulator

Purine
antimetabolite
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RRMS
SPMS

Intravenous Infusion
Mitoxantrone
Novantrone®
EMD Serono

Intercalates with
DNA; inhibits
topoisomerase II

Anti α4β1/ α4β7
integrin
monoclonal
antibody

Natalizumab

Tysabri®
Biogen

Alemtuzumab

Lemtrada®
Anti-CD52
Sanofi Genzyme monoclonal
antibody

Ocrelizumab

(Ocrevus®,
Genentech)

Anti-CD20
monoclonal
antibody

12 mg/m2 every 3
months until a
cumulative dose
limit of
approximately 140
mg/m2 is reached
300 mg every 4
weeks

RRMS
SPMS

12 mg per day
for 5 days in the
first year, 3 days
in second year
d
RRMS:
300 mg

RRMS

twice 14 days
apart, then 600
mg once every
24 weeks
PPMS: 300 mg
twice 14 days
apart, cycle
begins every 24
weeks

RRMS

RRMS
PPMS

Recent studies have shown that early treatment with disease modifying therapies (DMTs) is
associated with significant improvement in the patient’s quality of life (Kobelt, Lindgren, & Parkin,
et al, 2000). In addition, MS medications can help achieve treatment goals by treating acute relapses,
improve health-related QOL, reduce the frequency and severity of relapses, delay disability
accumulation, and postpone the onset of the progressive phase of the disease (Phillips, 2004;
Philips, 2009). For example, when acute exacerbations occur (such as vision loss or loss of
coordination), they are commonly treated with a short duration of high-dose oral or intravenous
corticosteroid. If spasticity occurs, it can be addressed with muscle relaxants, however therapy with
DMTs is designed to prevent relapses and progression of disability rather than treat specific
12

symptoms or exacerbations of the disease (Smith, Carson, & Fu, et al, 2010). These agents modify
the immune response that occurs in MS through various anti-inflammatory, immunomodulatory or
immunosuppressive effects. In 2018, the American Academy of Neurology (AAN) released new
guidelines on the use of disease-modifying therapies (DMTs) in patients with MS to provide
updated guidance on starting, switching, and stopping treatments including the recommendation
for an earlier start to treatment rather than later in the disease course (Rae-Grant, Day, Marrie, et
al, 2018).
Glatiramer Acetate
Among the DMTs available, glatiramer acetate stands out due to its unique mechanism of
action, and excellent long-term efficacy/safety data. Glatiramer acetate (GA) is the generic name
of a multiple sclerosis drug produced by Teva Pharmaceuticals and sold under the commercial or
brand name Copaxone®. Copaxone® (glaterimer acetate) was the first of the currently approved
DMTs to be tested in human subjects and is considered a standard choice for first-line treatment
of RRMS. Copaxone® (glatiramer acetae) was approved by the FDA in 1996 began development
at the Weizmann Institute in the 1960’s to study structural features of antigens involved in the
induction of the animal model of MS (Varkony H, Weinstein V, Klinger E, et al., 2009).
Glatiramer acetate is classified as a non-biological complex drug (NBCD) composed of a
mixture of immunogenic polypeptides of varying amino acid sequences and sizes that are
difficult to characterize even with state-of-the-art analytical methods (Weinstein, Schwartz,
Grossman, 2015). Glatiramer acetate is best described as a heterogeneous mixture of amino acid
copolymers. Thus, glatiramer acetate is not a single molecular entity, but a distinct synthetic
polypeptide comprised of varying lengths of interconnected peptide chains, some containing up
to 200 amino acids with structural complexity comparable to that of proteins, or even more
complex than proteins (Varkony, et al., 2009). Glatiramer acetate is a manufactured amino acid
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polymer of tyrosine, glutamate, alanine, and lysine analogous to biological products and thus is
defined by its well-controlled manufacturing process. Glatiramer acetate resembles the myelin
sheath components of myelin basic protein (MBP), which allows it to act as a decoy for immune
targeting of myelin. Glatiramer acetate is administered by subcutaneous injection every day at
the dose of 20 mg or alternatively three times a week at the 40 mg dose.
The exact mechanism of action (MOA) of glatiramer acetate is unknown, but it is
believed to function via a multifaceted affect involving both immunomodulation and
neuroprotection (Figure 2). Its MOA is hypothesized to involve competition with myelin
autoantigens at the major histocompatibility complex class II binding site on antigen-presenting
cells, induction of antigen-specific Th2 T cells leading to bystander suppression of inflammation,
and stimulation of neurotrophic factor secretion by immune cells (Schrempf & Ziemssen, 2007).
Figure 2: Glatiramer Acetate Mechanism in Immune Modulation. The proposed mechanism
of action relates to its immunologic effects such as the induction of antigen-specific suppressor T
cells, inhibition of antigen presentation, displacing bound myelin basic protein (MBP), or causing
an immune deviation in CD4_ T cells from a Th1 to a Th2 phenotype, which secrete antiinflammatory cytokines in the CNS through cross-recognition with myelin autoantigens through a
series of distinct steps (Schrempf & Ziemssen, 2007).

Across five randomized controlled clinical trials, glatiramer acetate 20 mg has
consistently demonstrated efficacy in reducing relapse rate and MRI disease activity and slowing
14

of disability progression in patients with RRMS, while possessing a favorable and wellcharacterized safety record in both short and long-term studies (Boster, Ford, Neudorfer, &
Gilgun-Sherki, 2015). Subsequently, the Glatiramer Acetate Low-Frequency Administration
(GALA) study demonstrated the efficacy and safety of glatiramer acetate 40 mg 3 times a week
in patients with RRMS (Khan, Rieckmann, Boyko, Selmaj, & Zivadonov, 2013).
Injectable DMTs such as glatiramer acetate have dominated the MS market for over two
decades, but the situation has changed because of the recent patent expirations of Teva’s
Copaxone® (glatiramers acetate). This created an opportunity for approval of generics through the
Abbreviated New Drug Application (ANDA) pathway established by the 1984 Hatch-Waxman
Act (Mossinghoff, 1999), which permits FDA approval of applications to market generic versions
of brand-name drugs without the need for costly and duplicative clinical trials. The FDA has made
accelerated or expedited approval of less costly generic drugs a core objective in its mission
designed to facilitate more generic competition, promote patient access, and improve the
economics of developing generic medicines. Unlike the standard FDA drug-approval process that
requires extensive preclinical (animal) and clinical (human) testing to establish safety and
effectiveness (Van Norman, 2016), the approvals of generic drug products via the ANDA pathway
do not generally require inclusion of preclinical and clinical data (Naziya, Sandeep, & Anoop,
2018). Instead, physicochemical equivalence and bioequivalence to the innovator drug must be
demonstrated scientifically to establish therapeutic equivalence (Chow, 2014).
When an innovative (or brand-name) drug product is going off patent, pharmaceutical or
generic companies may file an ANDA for generic approval, which in this scenario is for
Copaxone®. Generic drug products are defined as drug products that are identical to an innovative
(brand-name) drug which is based off an approved NDA with regards to active ingredient(s), route
of administration, dosage form, strength, and conditions of use. Since ANDA submissions for
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generic applications do not require lengthy clinical evaluation of the generic drugs under
investigation (see Table 2), the price of a generic drugs is usually much lower than the cost of the
originator brand. On average, generic entrants are about 30 - 60% of the price of the brand-name
original (Zarowitz, 2008, Lewek & Kardas, 2010). As a result, increased use of less expensive
generic drugs is encouraged as a means of healthcare savings and costs containment by policy
makers, insurers, providers, and patients.
Table 2: FDA NDA vs ANDA Approval Requirements (Chow, 2014)
NDA

ANDA

1. Chemistry

1. Chemistry

2. Manufacturing

2. Manufacturing

3. Controls

3. Controls

4. Testing

4. Testing

5. Labeling

5. Labeling

6. PK/bioavailability

6. PK/bioavailability

7. Animal Studies

7. ----

8. Clinical Safety & Efficacy Trials

8. ----

NDA = New Drug Application; ANDA = Abbreviated New Drug Application

In April 2015, the first generic version of the complex drug glatiramer acetate (Glatopa®
20 mg/mL) injection was approved in the United States as a fully substitutable AP-rated generic
for all approved indications of the 20 mg branded glatiramer acetate (Copaxone®) dosage form.
Despite glatiramer acetate’s complex nature of being a chemically synthesized mixture of random
peptide, the FDA approval occurred without conducting any clinical trials. Subsequently, the 40
mg Glatopa® formulation was approved in February 2018, while Mylan received FDA approval of
both its generic formulations in October 2017. Teva contends that Copaxone® is too complex for
another manufacturer to make an identical version of its drug, thus asserting that any new generic
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version of Copaxone should be tested in clinical trials with MS patients to assure its safety and
efficacy (FDA, 2015). Such a study has been conducted when the first phase III clinical trial to test
a generic disease-modifying medication for multiple sclerosis treatment entitled the Glatiramer
Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE), demonstrated that
glatiramer acetate, the generic drug, was equivalent to the trademark drug Copaxone® for the
treatment of MS (Cohen, Belova,, Selmaj, et al., 2015). Despite this clinical validation of generic
sameness to the originator or reference listed drug (RLD), lingering healthcare stakeholder
perceptions of this sameness versus potential difference concerns may remain a key influencer in
potential treatment utilization. As a result, some stakeholders may perceive that generics as less
expensive versions of the RLD, while others may believe that they are never fully identical to the
RLD.
Cost of Disease Modifying Therapies
Spending on prescription drugs in the United States is on the rise and is projected to outpace
growth in other parts of the healthcare sector in 2018 (Cuckler, 2017). In addition, in 2017 there
was a 14.6% increase in per member specialty drug spending, up from 10.1% the prior year.
Consequently, it is project that by 2022, specialty drugs will account for a projected 47% of the
pharmacy industry’s revenues. In 2017, four specialty classes accounted for over 75% of total
expenditure for specialty drugs: (1) inflammatory conditions, (2) MS, (3) cancer, and (4) human
immunodeficiency virus. Moreover, in recent years, the healthcare and managed care communities
have witnessed a huge shift in expenditure from medical benefits towards pharmacy benefits,
especially for newer oral agents that treat cancer or manage MS (Owens, 2013). Specialty drug
spending now represents 46.5% of the net per-capital spending in the US. Of the $12 billion in net
spending on new drugs, 75% was for specialty products exclusively (IQVIA, 2017). The IQVIA
study also found that found the use of copay coupons in 42% of all specialty prescriptions compared
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with 18% of all branded prescriptions filled through commercial plans. A contributing factor
supporting high DMT costs and copay coupon use is the reality that most patients do not have to
directly pay for their drugs. Copayments or out-of-pocket costs are meant to be paid by the patient,
which should theoretically keep prices low. However, many pharmaceutical companies have
counterattacked this by offering copayment coupons, which enable the company to pay some or all
the patients’ costs while raising drug prices (Dafny, Ody, & Schmitt, M.A, 2016). For specialty
conditions in which the initial cost of drugs is extremely high such as autoimmune diseases, hepatitis
C, and multiple sclerosis coupon usage rates are greater than 50% (IQVIA, 2017). This high
utilization of copay coupons is consistent with a study looking at the impact of patient copays or
co-insurance on the probability of receiving disease-modifying therapies and on being adherent with
treatment in patients with multiple sclerosis. The study confirmed that MS patients are sensitive to
cost sharing by having a lower probability of receiving DMTs, lower probability of treatment
adherence, and higher risk of treatment discontinuation (Palmer, Abouzaid, Shi, Fowler, Lenhart,
Dastani, & Kim, 2012). Patients who are not adherent to their DMTs have higher risk of relapse,
more emergency department visits and hospitalizations, and higher medical costs, thus reducing
cost barriers may improve initiation of DMTs and treatment adherence. Specialty copayments or
coinsurance is variable depending on the insurer but can range from as low as 20 percent or as high
as 50 percent of the cost of the medication. MS patients covered by Medicare Part D plans where
drugs costing $670 or more per month are placed on a “specialty tier,” may be subject to up to 33
percent coinsurance making it potentially difficult for Medicare patients to afford their medications
(Doshi, Ladage, Pettit, & Taylor, 2016).
Despite the availability of more treatment options, costs for all MS DMTs have increased
sharply in the United States (Sawad, Seoane-Vazquez, Rodriguez-Monguio, 2017). Between 2008
and 2012, U.S DMTs sales doubled from $4 billion to nearly $9 billion annually (Hartung,
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Bourdette, Ahmed, & Whitham, 2015). By 2013, first generation DMTs like IFNß-1b (Betaseron®)
and glatiramer acetate (Copaxone®) grew to an average annual cost of over $60,000. Second
generation DMTs (Oral agents) cost have increased from 8 % to 17 % annually since their approval.
For example: fingolimod cost $50,775 in 2010 but has increased in cost by 8% to $63,806 by 2013.
Similarly, with teriflunomide and dimethyl fumerate cost $47,651 and $57,816 respectively at
approval but increased in cost by 17% ($57,553) for teriflunomide and by 14% ($63,315) for
dimethyl fumerate (Hartung, Bourdette, Ahmed, & Whitham, 2015). Current annual wholesale
acquisition costs of commonly used DMTs are shown in below in Figure 3.
Figure 3: Commonly Prescribed MS DMT Annual Acquisition Cost (AnalySource, 2019)
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The high cost of MS DMTs in the United States is producing a cascade of negative effects
upon patients with MS and their medical care. This can cause private insurers and public insurance
regulatory bodies to require individuals with MS to meet specific criteria to obtain coverage for
DMTs (Hohol, Orav, & Weiner, 1999) or require high copays (Minden, Frankel, Hadden, &
Hoaglin, 2007). In what appears to be a direct response to the high cost of these drugs, insurance
carriers have developed tiered formularies requiring step-wise DMT trials, with the tiers apparently
determined by preferential pricing contracts rather than any objective analysis of risks and benefits
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of the various therapies (Miller, Happe, Meyer, & Spear, 2012; Owens, 2013).
Overall, MS is a very costly chronic disease, with direct costs of prescription drugs and
indirect costs being the most significant cost drivers, according to available data (Adelman, Rane,
& Villa, 2013). The cost of providing health plan benefits and insurance coverage for MS therapy
is one of the most rapidly growing segments of current healthcare expenditures. Evolving drug
complexity portends increasing complexity for payers and health plans. Therefore, improved action
plans must be developed that balance appropriate access to optimal therapies with the need to
manage the high costs of DMTs and evolving treatments. Generic drugs are one of the most
effective checks on rising drug costs in the United States (Kohl & Shrank, 2007). Today, about 9
out of 10 prescriptions filled with simple, small molecule generic drugs. However, most MS DMTs
are complex agents and not exposed to price competition from generics, except for the recent
availability within the glatiramer acetate category.
Healthcare Insurance Benefit Design
In the U.S., a health plan is an entity that provides or arranges for the insurance coverage
of specific health services for an individual or group, either for a pre-determined price or by
administering health benefits for entities like employers who opt to take on the financial risk
themselves, often referred to as self-insuring (Morrisey, 2008). Today, health plans play a central
role in the U.S. healthcare market by providing or administering health insurance as well as a
range of services to its members on behalf of employers, individuals and government payers. As
the country’s largest healthcare payer, the U.S. government has always influenced the benefit
design of Medicare, Medicaid, Veterans Affairs and the Department of Defense (Brown &
American Enterprise Institute for Public Policy Research, 2010). The U.S. government has
increased its influence by setting standards for more affordable and simplified benefit structures
that are reshaping traditional commercial health plan products thru bundled and value-based
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payment reimbursement.
In turn, private health plans must look for ways to control their expenses while
maintaining enough quality to satisfy the needs of their clients and members. Pharmaceuticals,
especially branded prescription drugs have been and will continue to be a top target for health
plan cost control due to their high category growth and spend (Ballreich, Alexander, Socal,
Karmarkar, & Anderson, 2017). However, health plans also know that pharmaceutical
innovations create some of the greatest opportunities for better health and decreased overall
costs. Government and private payers are trying to stabilize or reduce their healthcare spend by
shifting more costs to consumers (Jencks, & Schieber, 1992). This is occurring across the market
through higher deductibles, copays and premiums as well as greater use of coinsurance. It is most
prominent in consumer-directed health plans (CDHPs) and the use of private exchanges,
particularly for retirees. As consumers assume a higher share of healthcare costs, they face
greater responsibility for healthcare choices and spending.
Health plans typically organize their insurance services into three distinct areas of
coverage based on the patient lives that they cover (Hoffman, Klees, Curtis, 2000):
•

Commercial: People under 65 may have access to what is often called group coverage as
a benefit from their employer. If not covered under a group plan, the Affordable Care
Act, (ACA) requires individuals to purchase coverage through a health plan exchange or
face a penalty fee for remaining uninsured, but this is expected to end in 2019.

•

Medicare: People 65 and older, as well as permanently disabled individuals of any age,
have access to Medicare a federally-funded insurance program. Medicare beneficiaries
can choose to enroll in “traditional Medicare,” which is administered directly by the
federal government, or enroll in Medicare Advantage with a private plan that administers
the benefit on the government’s behalf.
21

•

Medicaid: People of all ages who meet a low income threshold may have access to
Medicaid a federally and state-funded insurance program. State governments may choose
to administer their Medicaid program themselves or outsource it to a private plan, often
referred to as a Managed Medicaid plan.
Over two-thirds of the U.S. population is enrolled in a commercial market plan (Barnett,

& Berchick, 2017). In addition, the U.S. Census Bureau shows 60 percent of Americans are
covered through an employer, 16.2 percent purchase health insurance directly, and the rest are
covered by Medicare (16.7 percent) or Medicaid (19.4 percent) or remain uninsured. Within this
payer mix, MS patients receiving glatiramer acetate treatment regiments will find varying
degrees of formulary coverage and benefit design relative to their insurer as shown in Figure 4.
Figure 4: Insurer Benefit Design Coverage for Glatiramer Acetate Therapies (Managed
Markets Insights & Technology, 2019)
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Medicare
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Medicaid
100%
Coverage
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Any private or public health plan that maintains a drug formulary irrespective of whether
they contract or negotiate for product access will utilizes a Pharmacy and Therapeutics (P&T)
Committee comprised of a medical director and/or prescribing physicians and the pharmacy
director to assist in development and management of benefit design. P&T Committees may also
include a nursing director or other allied care providers as well as a patient advocacy member
representative of real-world clinical practice and community use. The committee is charged with
developing and maintaining the drug formulary as well as analyzing new drug evaluations, new
FDA approved indications for existing drugs, new clinical line extensions, and new published or
clinical practice trends that may impact previous formulary placement decisions. Health plans
increasingly include cost data as part of the P&T committee review process. In the absence of
significant clinical differentiation, product formulary placement is likely to be financially
oriented or incentive-based providing financial incentives (i.e., lower copayments) for enrollees
to choose drugs that are preferred by the payer.
To slow and even reverse healthcare spend especially for specialty pharmaceuticals, health plans
have focused on specific pharmacy cost controls, including (Pharmaceutical Care Management
Association, 2016):
•

Changes to benefit design that shift costs to consumers:
•

Increased premiums

•

Increased deductibles

•

Increasing co-pays, using co-insurance, including extending cost-sharing to drugs
covered under the medical benefit, and increasing tier complexity.

•

Implementation of copay accumulator programs that enforces the patient’s full
payment of the deductible without subsidization from the manufacturer’s copay
program toward the cost of the drug.
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•

Access and utilization management tactics:
•

Employing approaches such as step therapy, prior authorization, the narrowing of
formularies with limited brands to decrease use of high cost drugs, encourage use of
lower cost options and generic utilization.

•

Implementing increasingly aggressive utilization management tools, including
expanded use of formulary exclusions and introduction of new to market policies and
NDC blocks.

•

Aggressively negotiating for price protection and rebates for preferred tier placement
with drug manufacturers.

The need for pharmacy cost control and greater financial predictability is a key driving
force behind pharmacy management tactics. Intense focus on specialty products have become a
target. Plans have publicly stated their expectations on cost cutting by greater use of generics and
biosimilars. Commercial, Medicare and Medicaid plans are increasingly challenged with
controlling the costs associated with specialty medications. Active management of specialty
drugs and the use of the best pharmacy go together in achieving great patient results with better
savings.
Plans have always controlled pharmaceutical utilization through formulary management.
However, the latest Utilization Management (UM) strategies particularly exclusion lists and
New-to-Market Blocks are designed to address issues of higher product volume for non-preferred
and/or high cost brands and pricing. These UM strategies continue to raise access hurdles and, in
some cases, prohibit access. In a survey conducted by the National Disability Institute (NDI) and
the Multiple Sclerosis Association of America (MSAA), results showed that access to health
insurance is not a barrier for MS patients with only 7.7% uninsured and coverage consisting of
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53.9% Commercial insurance and almost 39% received government funded healthcare, namely
32.5% Medicare and 6.0% Medicaid (National Disability Institute, 2012).
An additional system for driving generic drugs in the United States is one of “switching”
from a brand product to a generic equivalent (usually an AP or AB-rated generic in the Orange
Book). Depending upon individual State Law requirements and insurer, substitution may be
performed by a pharmacist for a prescription most often written as a brand name product and
without specified preference (i.e. dispense as written) to a less expensive generic option if
available with appropriate consent. One consequence of this system of substitution is that
patients may have their medication “switched” either from brand to generic or from one generic
to another generic without input from or knowledge of the physician or the patient without
appropriate notification (Shrank, et al, 2010).
Conclusion
MS is an inflammatory and degenerative disease of the CNS affecting young adults. The
burden of the disease in the society is very high representing the second cause of disability in
young patients. In addition, MS is a very costly disease with a significant economic burden to the
healthcare system. Given the prevalence of MS and increasing DMT utilization and costs
associated with management of the disease, economic evaluation is important in making
informed decisions. In a cost-conscious healthcare environment with ever growing fiscal
responsibility being placed upon healthcare delivery, cost effective therapies like generic DMTs
in MS are likely to become an important part of the decision- making process to use resources
efficiently in the face of rapidly escalating costs of MS.
This is an important area of research because of the very limited data analyzing the
utilization uptake of generic glatiramer acetate post FDA approval using electronic prescription
claims data. There currently are no large retrospective studies examining differences in generic
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vs branded GA uptake in the MS prescription treatment category between payer types. Using
prescription claims frequency or run rate trends, the investigators will create a linear regression to
forecast future utilization of glatiramer acetate. Secondly, the investigators will compare patient
out of pocket copayment costs between the three payer groups in addition to copayment card
utilization within the Commercially insured group.
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CHAPTER 3
METHODOLOGY

Research Design
A retrospective, observational quantitative archival data analysis of Commercially
insured, Medicare, and Medicaid prescription claims identified by 20 & 40 mg Copaxone®,
Glatopa®, and Mylan glatiramer acetate national drug code utilization.

Specification of Variables
Glatiramer acetate (GA) use was identified by approved and dispensed pharmacy
prescription fills in Commercial, Medicare, and Medicaid claims using national drug codes to
compare ratio of branded versus generic GA prescription claim volume to total GA DMT
prescription utilization. Glatiramer acetate prescription claims consisted of Copaxone®, Glatopa®,
and Mylan Glatiramer Acetate prescription utilization over 52-months inclusive of FDA approved
generic glatiramer acetate entrant timing within each of the three key insurance channels. In
addition, patients’ out-of-pocket copayment amounts for specific drugs were compared between
payer groups, as well as manufacturer prescription copayment coupon or foundational assistance
utilization within the various payment channels.

Data Sources
Symphony Health – Integrated Dataverse® data set from October 1, 2014 – January 31,
2019 licensed to Pfizer Inc. in connection to statement of work in de-identified format in
compliance with the Health Insurance Portability and Accountability Act of 1996 and its
implementing regulations (“HIPAA”). Symphony Health – Integrated Dataverse® de-identified
claims data set fields available for analysis are shown in Table 3 of the Appendix.
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Data Set Construction
1. Monthly prescription claims for Copaxone®, Glatopa® and Mylan Glatiramer Acetate
(numerators). Specific National Drug Code (NDC) numbers included in the data set:
•

Copaxone®: 06854631730 (20 mg 30 Pre-filled Glass Syringe Blister Pack in 1 Carton)
and 06854632512 (40 mg 12 Pre-filled Glass Syringe Blister Pack in 1 Carton)

•

Glatopa®: 00781323434 (20 mg 30 Pre-filled Glass Syringe Blister Pack in 1 Carton)
and 00781325089 (40 mg 12 Pre-filled Glass Syringe Blister Pack in 1 Carton)

•

Mylan Glatiramer Acetate: 00378696093 (20 mg 30 Pre-filled Glass Syringe Blister
Pack in 1 Carton) and 00378696112 (40 mg 12 Pre-filled Glass Syringe Blister Pack in 1
Carton)

2. October 1, 2014 – January 31, 2019 total FDA approved glatiramer acetate DMT claims
(denominator).
3. Prescription claim coverage and transactional specifics for Copaxone®, Glatopa® and Mylan
Glatiramer Acetate including utilization of out-of-pocket support in the form of copay or
secondary assistance from a prescription assistance program.
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Data Analysis
1. Calculated monthly uptake of each glatiramer acetate (GA) by insurance payer
(Commercial, Medicare, and Medicaid) by comparing prescription claim volume of
utilization to total GA DMT utilization. The claims ratio is used to construct three
different growth curves showing the uptake trends for each version of glatiramer
acetate.
•

A future growth curve of branded and generic utilization was constructed based on
percentage increases and compared to previous period to forecast projected
utilization based upon regression analysis for the remainder of 2019 insurer benefit
cycle.

2. Mean monthly dollar value of patient out-of-pocket costs compared between
Commercial, Medicare and Medicaid insurance groups for each glatiramer acetate
medication.
• Percentage of claims with manufacturer or foundational copay assistance per insurer
type.
•

Commercial insurance: Percent of claims that have utilized manufacturer
copayment cards.

•

Medicare: Percent of claims with free or reduced cost prescription offers for
those qualifying either for patient assistance programs or those eligible for
Medicare “extra help” assistance.

•

Medicaid: Percent of claims with zero cost or prescription patient assistance as
a low-income subsidy.

Institutional Review Board
Symphony Health Integrated Dataverse® claims data set licensed by Pfizer Inc. is de30

identified and qualifies as non-human research as set forth by the guidelines of the MUSC
Institutional Review Board.

Conceptual Model
A review of the literature on brand vs generic glatiramer acetate utilization in the
management of relapsing remitting multiple sclerosis reveals a lack of comprehensive
theoretical framework for understanding these events and their complexities. Applying a
process of conceptual framework analysis, as shown in Figure 5, will provide a theoretical
framework to shed new light on the feasibility of implementing sustainable generic
prescribing practices. This study will contribute important informational insights on MS
brand vs generic utilization and help provide additional context to possible influences in
generic drug prescribing or switching.
Figure 5: Project Conceptualization Chart: A conceptual diagram outlining the study
methodology and data analysis.
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Dear Editor,
Please find enclosed our manuscript submission entitled: “Prescription Trends in Branded
Versus Generic Glatiramer Acetate Utilization Among Insurers for the Treatment of Multiple
Sclerosis in the United States.” The study provides insight on current trends in generic glatiramer
acetate (GA) utilization across various payment channels based upon recent availability. The
utilization of lower cost generics over branded offering could result in healthcare savings.
Rising healthcare spend on multiple sclerosis (MS) drugs raises the question of what role
does a generic glatiramer acetate have within MS treatment or acceptance by stakeholders.
Notably, no study has specifically evaluated the differences in utilization uptake of branded vs
generic GA among the major insurer categories. The purpose of this study is to establish whether
insurer type affects the rate of utilization uptake of branded vs generic GA.
To address this research gap, we extracted glatiramer acetate prescription records from
Symphony Health Integrated Dataverse® archival billing data for patients covered by
Commercial, Medicare, and Medicaid for 52 months from Oct. 2014 – Jan. 2019. Our analysis
of glatiramer acetate claim rates revealed a substantially lower utilization of generic glatiramer
acetate across all payer types compared to the brand. The greatest increases in generic were
observed in Commercial and Medicare patients. The results indicate a significant brand
preference with low payer management directing glatiramer acetate prescriptions toward the
generic options.
Thank you for considering our manuscript for publication. We appreciate your time and
look forward to your response.
Respectfully,

Kit N. Simpson, DrPH
Professor
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ABSTRACT

BACKGROUND: Glatiramer acetate has been a core component of disease modifying therapy
for multiple sclerosis since its introduction in 1996. However, branded glatiramer acetate has
increased in acquisition cost by approximately 1000% to approximately $90,000 per year.
Because of the drug’s high cost and availability of alternative lower cost generic options, insurers
may use various strategies to control branded utilization, while encouraging generic alternative
use.
OBJECTIVE: To observe and report variances of generic vs branded glatiramer acetate
utilization by insurance type.
METHODS: Final approved nationwide pharmacy transactional claims for Copaxone®,
Glatopa®, and Mylan Glatiramer Acetate were extracted from Symphony Health Integrated
Dataverse® data set from October 1, 2014 – January 31, 2019 for Commercially insured,
Medicare beneficiaries with supplemental insurance, and Medicaid patients. Branded versus
generic glatiramer utilization rates were calculated based upon volume and using simple percent
change projection and regression modeling. Patient out-of-pocket costs and prescription
assistance were categorized by insurance payment type.
RESULTS: Over the 52-month period, 111,906 patients with multiple sclerosis were prescribed
glatiramer acetate by Neurologists (80%) and had 1,624,159 approved dispensed claims
primarily through specialty mail (87%) and categorized by payment type as 63.2% Commercial,
25.4% Medicare, and 11.8% Medicaid. The market trend showed a consistent decline in
branded glatiramer acetate claims offset by increasing uptake in generic glatiramer acetate with
the launch of additional generic market entrants. Generic market share has continued to grow
reaching an approximate 30% share of claims. Branded glatiramer acetate utilization has
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declined by more than 56%, while generic claim volume has grown 155% over the past 16
months. Among the payer types, Medicare has observed the greatest brand decline at 70% and
the second highest generic utilization. Commercial insurers have the greatest category claim
volume and greatest generic growth to a 26% share, while the brand has declined by 44%.
Medicaid has had the lowest utilization volume and the greatest ratio of generic utilization
among insurers at 45%. Patient out of pocket costs are highest with branded use across all
insurer types, while Medicaid has the lowest patient out-of-pocket costs.
CONCLUSIONS: The study revealed that generic glatiramer acetate adoption or utilization
has been slow among insurers but increasing over the past sixteen months with additional
generic glatiramer acetate entrants and increased price competition. The greatest trend in
generic utilization is occurring within the Commercial channel followed by Medicare and then
Medicaid, which has had the lowest growth trend. The results indicate that barriers to generic
glatiramer acetate may vary by insurer and influenced by prescriber or patient choice. Generic
uptake is projected to increase across all insurer types reflective of trends during 2019 open
enrollment and healthcare benefit design change associated with a new health insurance cycle.

SUMMARY BULLETS
What is already known about this subject
•

Glatiramer acetate is a structurally complex, nonbiologic, established as an
effective treatment for multiple sclerosis with a well-recognized safety and
tolerable profile

•

Branded multiple sclerosis drugs have high yearly costs adding to high long-term pharmacy
costs.

•

Strategies to decrease healthcare costs include increasing the use of generic drugs through
brand-name drug utilization management.
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What this study adds
•

Examines differences in utilization rates by payer type for branded versus generic
glatiramer acetate over the past 52 months.

•

Forecasts future utilization of generic glatiramer acetate options relative to brand.

•

Compares differences in the patient out-of-pocket costs between payment types.
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INTRODUCTION
Multiple sclerosis (MS) is a common neurologic disease affecting more than 1 million
people in the United States.1 The etiology is assumed to be an autoimmune process leading to an
inflammatory condition that damages the myelin of the central nervous system and causes
progressive neurologic impairment and frequently severe disability.2
In the absence of a cure, MS therapy consists primarily of supportive care and symptomatic
management, which may generate substantial direct costs. Management of multiple sclerosis has
evolved in recent years, due in part to the availability of first generation and newer disease
modifying therapies (DMT) that are immunomodulating with improving efficacy, convenience, and
higher associated cost.3,4 However, these newer DMT’s with improved clinical benefits are often
associated with adverse events (AEs) that are uncommon, but significant, such as progressive
multifocal leukoencephalopathy (PML) or cardiac arrhythmias.5 Glatiramer acetate is the most
frequently prescribed DMT for MS, with an efficacy, safety, and tolerability profile backed by over
two decades of real-world and clinical data.6
Teva’s glatiramer acetate (Copaxone®) is a first generation DMT approved in 1996 to treat
multiple sclerosis. It has quickly proved effective, popular and a mainstay of first line treatment
among healthcare professionals and patients, gaining a reputation for turning multiple sclerosis into
a manageable chronic disease.7 , 8 Glatiramer acetate is considered a high-cost specialty drug.
Specialty drugs are typically high price products used to treat rare, complex conditions with
characteristics that may impede generic substitution or interchangeability.8 Branded glatiramer
acetate (Copaxone®) has increased in price by 1000 percent and now costs approximately $7,000
per month/$88,000 per year.1 0
Payers encourage the use of generic drugs to lower total drug spending with generic drugs
representing 89% of all prescriptions.11 This can be achieved by increasing management utilization
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of branded drugs such as prior authorization or step therapy, leveraging mandatory generic autosubstitution pharmacy switches or offering lower patient copayment on generic drugs.12 Generic
price competition has historically been a successful strategy for lowering prescription drug prices
in the United States.13 Specialty drugs, including injectables and generics may be an exception due
their use in complex situations like critical care, cancer, and autoimmune disease due to higher
escalating price increases that drive up cost.14 In addition, pharmaceutical manufacturers differ in
how they approach their pricing strategies, both for a new generic launch or for the defense of a
brand name drug. As a result, the presence of pre-existing or re-negotiated contracts may create
financial incentives (spread compensation) for a payer to stay with the branded drug for a longer
time, rather than automatically switch to the new generic without the appropriate financial
incentives15.
In April of 2015, the FDA approved the first fully AP substitutable generic version of the
glatiramer acetate called Glatopa in the United States.16 As the first U.S. generic manufacturer of
glatiramer acetate, Sandoz/Momenta launched the 20 mg generic formulation in June 2015 at a
15% discount to the wholesale acquisition (WAC) price of the brand-name Copaxone.17 In October
2017, Mylan received Food and Drug Administration (FDA) approval of a second 20 mg generic
version and the first 40 mg generic version of Teva’s multiple sclerosis medicine Copaxone
including pricing both at a 30% discount.18 Subsequently, Sandoz/Momenta received approval on a
40 mg generic version of Teva’s Copaxone in February 2018 matching the Mylan market pricing
approach.19 In June 2018, Mylan further reduced their WAC price discount compared to Teva’s
Copaxone by approximately 66% or a flat $1,950 per month acquisition cost.20 As a result, Teva
and Sandoz are likely to offer additional discounts or rebates to customers in an attempt match
Mylan’s pricing out of competitive pressure in order avoid losing formulary status or market share.
Whether these negotiated discounts or rebates will be passed on to patients at pharmacy point of
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sale points or withheld for insurer/pharmacy benefit manager profit remains to be determined.
Little is known about glatiramer acetate utilization in the treatment of patients with
multiple sclerosis among insurers after expiration of market exclusivity for the brand-name
medication (Copaxone®). In this study, we aim to examine trends in utilization and
management among insurers associated with branded versus generic glatiramer acetate
availability.
METHODS
We conducted a retrospective analysis of de-identified prescription pharmacy claims and
eligibility data extracted for the period October 1, 2014 – January 31, 2019 using Symphony Health
Integrated Dataverse® claims data identifying Copaxone®, Glatopa®, and Mylan Glatiramer Acetate
National Drug Code (NDC) numbers using final approved and dispensed prescription fills in
patients with multiple sclerosis. To compare different formulation quantities of medication, fills
were standardized to represent a single month’s glatiramer acetate supply (30 day) for the
recommended dose for relapsing remitting multiple sclerosis (20 mg/day and 40 mg three times a
week) and aggregated.
Our primary aim was to understand shifts or trends in treatment usage from brand to generic
glatiramer acetate agents over the study period. We calculated the market share of glatiramer
acetate drugs over time among the generic option relative to brand for therapy. Uptake of generic
glatiramer acetate was estimated as the percentage of all glatiramer acetate fills for which the
generic product was dispensed relative to brand. Two forecasting growth charts were constructed to
predict future uptake growth for glatiramer acetate within the Commercial, Medicare, and
Medicaid insurance groups. Branded and generic growth is calculated using a fixed percentage
change each month based on the observed rate each monthly period from October 2014 to January
2019, plus projected another 11 months for the brand.
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Secondary analyses compared the mean monthly patient out of pocket costs across the three
payment types. In addition, we examined the percentage of claims receiving prescription assistance
either from a manufacturer copayment program or foundational assistance that effectively reduces
or zero’s patient out-of-pocket expense.
The study was exempt from institutional review board review, as only a limited dataset was
accessed in full compliance with the Health Insurance Portability and Accountability Act of 1996.
RESULTS
From October 2014 to January 2019, 111,906 patients with multiple sclerosis were
prescribed glatiramer acetate. As shown in Table 1, patient demographics were consistent with
disease epidemiology. Most patients were female (77%) between the age of 31 – 60 (67%) with
a similar geographic distribution. Primary insurance coverage was 63.2% Commercial, 25.4%
Medicare, and 11.8% Medicaid. The primary prescriber of glatiramer acetate is a Neurologists
(80%) and the vast majority of the 1,624,159 approved claims dispensed were through a
specialty mail order pharmacy (87%).
Figure 1 shows the market trend of a consistent branded glatiramer acetate claim decline
offset by a rapid uptake in generic glatiramer acetate (Glatopa® 20 mg) with its initial market
entry and then remaining flat until launch of next generic entrant (Mylan 20/40 mg GA).
Generic market share has continued to grow reaching an approximate 30% share of claims as of
January 2019. Over the 52 months brand glatiramer acetate utilization has declined more than
half at 56%, while generic claim volume has grown 155% over the past 16 months.
Figure 2 shows the relative claim volume by payment type for comparison. Among the
payer types, Medicare has observed the greatest brand decline at 70% and the second highest
generic utilization uptake at a 28% share. Commercial insurers have the greatest category claim
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volume and greatest generic growth to a 26% share, while the brand has declined by 44%.
Medicaid has had the lowest utilization volume and the greatest ratio of generic utilization among
insurers at 45%.
Figure 3 shows projected or forecast branded utilization decline is greatest within the public
insurance channel (Medicaid & Medicare). Medicare has the greatest forecast decline in brand
utilization. Figure 4 reflects the projected generic utilization rate being greatest within the
Commercial channel, while lowest in Medicaid.
Table 2 compares mean monthly patient out-of-pocket (OOP) costs for glatiramer acetate
versions between Commercial, Medicare, and Medicaid insurers. Medicare has the highest patient
cost share among insurers with both branded and generic glatiramer acetate having the highest
mean OOP cost ($403 vs $330). Lower mean patient out-of-pocket costs are generally observed
with generic glatiramer acetate options based upon monthly medication fulfilment. Medicaid has
the lowest cost share among the three insurer types. Across all payment types, generics offer
approximately a 20% discount to the brand in patient out of pocket costs. Manufacturer copay
coupon or foundational assistance is also provided for both brand and generic glatiramer acetate to
assist with patient affordability. A greater degree or percent of assistance for $0 patient pay is
observed within Medicaid, while Medicare patients also have benefited from foundational assistance
and Commercial patients utilize manufacture copay coupons, which appears higher with generics
than brand.
DISCUSSION
Switching branded to generic medications has been a common cost containment measure
among insurers.21 Brand to generic switching is also common place across many therapeutic areas.
In this retrospective, observational study of brand versus generic glatiramer acetate (GA) utilization
among various insure types over 52 months, we found that generic utilization is occurring, but at a
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much slower rate and still evolving among insurers. In our analysis there is still a disproportionally
greater utilization of branded GA versus the generic glatiramer acetate across all insurer types,
although it is declining over time. This preference for the brand may reflect historical brand loyalty
or a lack of provider, patient, or insurer incentive to change to the generic unless by choice or
select insurer mandate.22 The decline in branded glatiramer acetate does not appear to be offset by
the degree of increasing generic utilization, so it may be indicative that patients may be switching
to other branded DMT therapies. In addition, standard generic switch models of brand conversion
rely on mandatory generic auto-substitution by pharmacists, which does not appear to be
occurring.23 However, increasing generic utilization over the past 16 months has improved
dramatically with the additional generic introduction of Mylan’s glatiramer acetate at its significant
discounted list price. The overall increased market utilization of generic glatiramer acetate appears
to be consistent across insurers and the utilization trend appears to be continuing through at least
the first month of the new 2019 benefit cycle. This may be indicative of changes in benefit design
or formulary administration favoring greater preferred generics utilization that assists in controlling
drug costs benefiting insurers, providers, and patients.
Healthcare benefit policies are continuously adjusted to improve value relative to quality
healthcare delivery.24 This can result in more costs being shifted to the beneficiaries, raising issues
in affordability especially for the high cost specialty pharmacy category multiple sclerosis disease
modifying therapies. These cost shifts can include higher yearly premium increases, rising
deductible limits or implementation of copay accumulator programs, greater utilization of
coinsurance requiring beneficiaries to pay a greater percentage of the full cost of a drug, and
benefit design changes that may eliminate coverage of a drug or move a drug from a lower price
tier to a higher one including generic drugs normally on the less expensive tier 1 or 2, to the much
more expensive 4th or 5th specialty tiers.25 This effectively eliminates any preferred drug advantage
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between a generic vs brand option in a category like specialty multiple sclerosis drugs and requires
patients to share a higher cost of these medications. It forces patients to pay increased out-ofpocket (OOP) costs for important specialty drugs that likely have no medically comparable
alternatives for treating a serious condition cost effectively.26 Patient OOP’s are a key lever in
product decision making and selection as many insurance beneficiaries are on fixed incomes such
as retired or disabled Medicare patients, low income/uninsured Medicaid participants, or even
middle class Commercial lives with low annual per capita incomes where high out-of-pocket health
care costs can pose a challenge in those with significant medical needs that are having to pay more
for healthcare delivery. Thus, the use of lower cost generic drugs would seem to make more sense
from a patient affordability or economic perspective.
Economics or financial incentives may also be a key influencer in insurer decision
regarding preferred brand or generic utilization.27 Insurers may be motivated to shift financial risk
exposure to the patient or improve internal operating margins. This influence can create misaligned
incentives whereby insurers or their pharmacy benefit managers (PBM) structure benefit design
based on self-benefiting financial profit motives relative to manufacturer negotiated preferred
product formulary tier positions that lead to greater retained rebates and discounts paid for insurers.
In theory, these discounts or formulary structures should benefit patient product access or
affordability directly at a pharmacy point of sale where a prescription is dispensed leading to both
lower patient OOP’s and pharmacy drug costs. Unfortunately, most patients pay their out-of-pocket
costs based on the list price of the drug, not on the discounted price given by the drug company. As
a result, insurers may have incentives to continue using an expensive specialty branded drug like
Copaxone® instead of a generic simply based upon the economics. To address both high costs and
access restrictions to all available multiple sclerosis treatments, greater transparency and financial
disclosures between policy makers, insures, and pharmaceutical companies are required. However,
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for commercial patients, high out-of-pocket cost shifts can also be addressed by drug manufactures
in the form of copay assistance cards that manufacturers provide to patients in order increase the
utilization of branded drugs despite the cost. These copay coupons or vouchers work by paying the
patient’s required portion of payment and could also explain why branded glatiramer acetate is
used disproportionately to the generic.
Public insurers like Medicare, created to increase access to prescription drug treatment
among beneficiaries, may also shift costs of specialty drugs to beneficiaries. Medicare plans, which
are administered by the same Commercial insurers and PBMs can charge between 25% and 33%
coinsurance for specialty tier drugs before enrollees reach the coverage gap or “doughnut hole”
where they have paid anywhere for 25-45% of the cost of their drugs. Once their total out-ofpocket spending exceeds an annual threshold of $5,100 in 2019, enrollees pay 5% of the total drug
costs above the catastrophic coverage threshold.28 As a result, Medicare beneficiaries may pay
more for the brand in theory, but secondary insurance obtained as part of a retirement benefit or
prescription assistance programs from foundations can cover or offset the higher monthly cost of
using a brand. This would explain why brand utilization is still dominate in our study. The
importance of secondary assistance is captured in our data analysis by the observation of a
significant drop in brand utilization in second quarter 2016, when the Department of Health and
Human Services Office of Inspector General (OIG) issued an OIG Advisory opinion stating that
charity prescription assistance programs (PAP) cannot be supported through drug manufacturer
donor (or its affiliate) contributions that exerts any direct or indirect influence or control over the
PAP due to perceived violation of Anti-Kickback Statutes. The elimination of donations by
manufacturers and the closure of PAP charities resulted in a decrease in secondary assistance
available to help pay for the higher costing brand. As a result, the beneficiary cost shift not only
helps explain the dramatic drop in brand utilization but also may explain the more recent increase
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in generic utilization simply based upon affordability for some patients. Medicare patient out-ofpocket costs in general for specialty products are higher for the brand compared to a less expensive
generic alternative.
In our analysis, Medicaid had the lowest utilization of either brand or generic GA compared
to either Commercial or Medicare payment types. As stated previously, Medicaid provides health
coverage for some low-income and uninsured individuals or nonelderly adults that are the least
likely to be able to afford expensive specialty drugs. Oversight by the Department of Health and
Human Services requires states to provide drugs to Medicaid beneficiaries without excluding even
these high cost specialty therapies. However, Medicaid pays some of the lowest costs for
pharmaceuticals as Medicaid plans receive supplemental rebates from manufacturers to lower
government spending on prescription drugs. This allows states to create a preferred drug list
encouraging physician to only prescribe therapies on that list, which are often more affordable and
have the greatest negotiated supplemental rebates provided by manufacturers. Although prior
authorization normally is utilized to manage high cost drugs by encouraging generics or excluding
non-preferred tier drugs, states are almost always required to provide access to drugs from
manufacturers that have signed a rebate agreement with the state. This allows brand manufacturers
to not only compete on price with generics, but also gain preferred coverage status and higher
potential utilization as seen in our analysis. Even with healthcare reform expanding Medicaid
eligibility in many states thereby improving access to MS treatments, the high cost of MS DMTs
can still be prohibitive even if supported by prescription assistance programs that may even assist
in covering costs of high risk insurance plans or even elderly patients Medicare premiums if
eligible.
Considering generic glatiramer has been availability since 2015, decreased usage may
reflect delayed formulary inclusion because of benefit design negotiations cycles or insufficient
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stakeholder motivation for action either from an economic, clinical, or behavioral perspective.
Despite obvious lower list prices with generics and the potential impact of direct multiple sclerosis
pharmacy cost reductions and patient OOPs, some stakeholders may harbor clinical reservations or
concerns about using these newer generic options in an immune mediated condition without more
patient exposure experience or until insurer incentives are employed that mandate generic first use
or incentivize pharmacy mediated auto-substitution. Either should be achieved through an aligned
process of strong insurer incentives to drive generic utilization via standard benefit design and
formulary management, improved communication between payers, physicians, pharmacists, and
patients on generic advantage to decrease healthcare costs, and educational initiatives to improve
confidence and trust in generic use in multiple sclerosis as a safe and effective alternative to the
brand. It is critical to effectively manage patient outcomes and associated costs by selecting and
using the most cost-effective drugs for formulary inclusion with the appropriate utilization
management incentives to drive usage.
The strength of this study is our ability to report changes in utilization patterns of brand
versus generic glatiramer acetate over 52 months inclusive of two generic entrants. However,
several limitations are warranted for consideration. First, this claims data set does not identify
intent of medication prescribing or usage by either physician or patient. Improved data reporting
and analysis could be improved by factoring prescriber/patient longitudinal information to more
accurately show insights on claim trends and volume. Second, the Symphony Health Integrated
Dataverse® claims data set is a blend of captured adjudicated pharmacy life cycle claims (43%),
final pharmacy non-life cycle claims that are only report final transactional status (51%), and a small
proportion of medical benefit claims (6%). As a result, not all data sets or fields are available thus
limiting depth of analysis and basis for categorization as an un-projected data set.
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CONCLUSION
The purpose of this study was to examine whether insurance type affected the rate of
utilization uptake of generic glatiramer acetate over 52 months inclusive of FDA approval of these
new low-cost options for multiple sclerosis treatment. The study revealed that utilization of generic
glatiramer acetate has been limited among insurers but has been increasing over the past sixteen
months as more generic GA options are available and price competition increases. Generic uptake
is projected to increase across all insurer types. A recent increase in generic utilization over the past
five months is indicative of a changing benefit design and reflective of 2019 open enrollment and
in anticipation/execution of a new health insurance coverage cycle. Lower patient out-of-pocket
costs and generic preferred formulary positioning will drive uptake rates for those with the greatest
cost shift risk. Patients in our analysis had higher out-of-pocket costs when using the brand versus
the generic option.
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Table 1: Baseline descriptors of pharmacy claims data set for
glatiramer acetate from October 2014 through January 2019
Patient Characteristics (n=111,906)
n
Sex
Female
86,283
Male
25,500
Other
123

%
77.10
22.79
0.11

Age Distribution
0 - 10
11 - 20
21 - 30
31 - 40
41 - 50
51 - 60
61 - 70
71 - 80
Unknown

18
627
6,085
18,128
25,981
31,099
22,998
6,968
2

0.02
0.56
5.44
16.20
23.22
27.79
20.55
6.23
0.00

Payer Type
Commercial/other
Medicare
Medicaid

70,725
28,442
12,739

63.20
25.42
11.38

Geographic Region
Northeast
Midwest
South
West
Other

26,237
27,010
36,124
21,494
1041

23.45
24.14
32.28
19.21
0.93

n

%

1,408,597
140,636
65,434
9,492

86.73
8.66
4.03
0.58

1,290,990
73,198
63,385
55,459
34,263
106,864

79.49
4.51
3.90
3.41
2.11
6.57

Claim Characteristic (n=1,624,159)
Pharmacy Type
Mail Order
Retail
Non-retail
Specialty
Physician Specialty
Neurology
Neurophysiology, Clinical
Family Practice
Family Medicine
Internal Medicine
Other
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Figure 1: Over the course of 52 months branded glatiramer acetate has been declining, while
generic utilization has increase based upon new market entrant launches and market price
adjustments. Branded glatiramer acetate utilization has declined 56%, while generic claim
volume has grown 155% over the past 16 months. The decline in branded utilization may be
contributed to generic utilization, switches to other MS DMT products, or treatment termination.
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Figure 2: Bar chart depiction of monthly brand versus generic glatiramer acetate claim volume by
primary insurer type. Commercially insured accounts for the greatest volume of both brand and
generic utilization followed by Medicare, while Medicaid has the lowest utilization volume.
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Figure 3: Trends in brand and generic glatiramer acetate utilization from October 2014 – January
2019 including projection through the next eleven months to December 2019. The projected
percent change decline in brand use is lowest within the Medicare channel, while greatest in
Medicaid. Generic utilization rate is greatest within the Medicare channel, while lowest in
Medicaid.
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Table 2: Table comparing mean monthly patient out-of-pocket (OOP) costs between
Commercial, Medicare, and Medicaid insurers. Greatest patient cost share is associated with
branded glatiramer acetate use and highest within the Medicare channel where higher
coinsurance is predominant. Lower patient out-of-pocket costs are observed with generic
glatiramer acetate options based upon monthly medication fulfilment. Medicaid has the lowest
cost share among the three insurer types, but also has the largest proportions of patients receiving
prescription assistance. All insurer types have a proportion of patients receiving prescription
assistance.
Share of $0
Patient Pay

Mean Monthly
OOP

Minimum
OOP

Maximum
OOP

Commercial
Copaxone

13%

$300

$0

$9,279

Glatopa

43%

$201

$0

$6,988

Mylan GA

23%

$224

$0

$6,988

Medicare
Copaxone

21%

$403

$0

$9,273

Glatopa

38%

$339

$0

$3,900

Mylan GA

32%

$317

$0

$3,986

Medicaid
Copaxone

34%

$80

$0

$7,003

Glatopa

45%

$3

$0

$1845

Mylan GA

47%

$16

$0

$4,499
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APPENDIX
Table 3: Symphony Health -Integrated Dataverse® True Benefit Design de-identified claims data
set fields licensed by Pfizer Inc.
ColumnName
PATIENT_ID
CLUSTER_ID
RX_ORDER
YEAR_MONTH
FLAG_LIFE
PHARMACY_TYPE
PATIENT_AGE_GRP
PATIENT_GENDER
INITIAL_PRODUCT
INITIAL_DRUG
INITIAL_GENERIC
INITIAL_BRAND_GENERIC_IND
INITIAL_PRODUCT_STRENGTH
INITIAL_DRUG_QTY
INITIAL_PRODUCT_FORM
INITIAL_NDC
INITIAL_DAYS_SUPPLY_GROUP
INTERIM_PRODUCT
INTERIM_DRUG
INTERIM_GENERIC
INTERIM_BRAND_GENERIC_IND
INTERIM_PRODUCT_STRENGTH
INTERIM_DRUG_QTY
INTERIM_PRODUCT_FORM
INTERIM_NDC
INTERIM_DAYS_SUPPLY_GROUP
FINAL_PRODUCT
FINAL_DRUG
FINAL_GENERIC
FINAL_BRAND_GENERIC_IND
FINAL_PRODUCT_STRENGTH
FINAL_DRUG_QTY
FINAL_PRODUCT_FORM
FINAL_NDC
FINAL_DAYS_SUPPLY_GROUP
SUBSTITUTION_FLAG
MULTI_PAYER_FLAG

ColID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
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DataType
VARCHAR2 (20 Byte)
VARCHAR2 (61 Byte)
NUMBER
VARCHAR2 (6 Byte) 'YYYYMM'
VARCHAR2 (14 Byte)
VARCHAR2 (30 Byte)
VARCHAR2 (7 Byte)
VARCHAR2 (6 Byte)
VARCHAR2 (60 Byte)
VARCHAR2 (60 Byte)
VARCHAR2 (60 Byte)
CHAR (1 Byte)
VARCHAR2 (10 Byte)
NUMBER
VARCHAR2 (40 Byte)
CHAR (11 Byte)
VARCHAR2 (7 Byte)
VARCHAR2 (60 Byte)
VARCHAR2 (60 Byte)
VARCHAR2 (60 Byte)
CHAR (1 Byte)
VARCHAR2 (10 Byte)
NUMBER
VARCHAR2 (40 Byte)
CHAR (11 Byte)
VARCHAR2 (7 Byte)
VARCHAR2 (60 Byte)
VARCHAR2 (60 Byte)
VARCHAR2 (60 Byte)
CHAR (1 Byte)
VARCHAR2 (10 Byte)
NUMBER
VARCHAR2 (40 Byte)
CHAR (11 Byte)
VARCHAR2 (7 Byte)
CHAR (1 Byte)
CHAR (1 Byte)

COPAY_CARD_FLAG
INITIAL_PAYMENT_TYPE
INITIAL_BADMIN_NAME
INITIAL_MCO_NAME
INITIAL_PLAN_NAME
INITIAL_PLAN_TYPE
INITIAL_PLAN_SUB_TYPE
INTERIM_PAYMENT_TYPE
INTERIM_BADMIN_NAME
INTERIM_MCO_NAME
INTERIM_PLAN_NAME
INTERIM_PLAN_TYPE
INTERIM_PLAN_SUB_TYPE
FINAL_PAYMENT_TYPE
FINAL_BADMIN_NAME
FINAL_MCO_NAME
FINAL_PLAN_NAME
FINAL_PLAN_TYPE
FINAL_PLAN_SUB_TYPE
INITIAL_CLAIM_STATUS
INITIAL_REJECT_CDE
INITIAL_REJECT_REASON
INITIAL_REJECT_GROUP
INITIAL_MACRO_REJ_GROUP
INITIAL_SOB
INTERIM_CLAIM_STATUS
INTERIM_REJECT_CDE
INTERIM_REJECT_REASON
INTERIM_REJECT_GROUP
INTERIM_MACRO_REJ_GROUP
INTERIM_SOB
FINAL_CLAIM_STATUS
FINAL_REJECT_CDE
FINAL_REJECT_REASON
FINAL_REJECT_GROUP
FINAL_MACRO_REJ_GROUP
FINAL_SOB
INTERIM_TIME_TO_FILL
FINAL_TIME_TO_FILL
MEDICARE_ELIGIBILITY
INITIAL_APP_CLAIM_CNT
INITIAL_REJ_CLAIM_CNT
NN_INITIAL_APP_CLAIM_CNT

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
59

CHAR (1 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (250 Byte)
VARCHAR2 (250 Byte)
VARCHAR2 (250 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (250 Byte)
VARCHAR2 (250 Byte)
VARCHAR2 (250 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (250 Byte)
VARCHAR2 (250 Byte)
VARCHAR2 (250 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (10 Byte)
CHAR (8 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (100 Byte)
VARCHAR2 (60 Byte)
VARCHAR2 (13 Byte)
VARCHAR2 (13 Byte)
CHAR (8 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (100 Byte)
VARCHAR2 (60 Byte)
VARCHAR2 (13 Byte)
VARCHAR2 (13 Byte)
CHAR (8 Byte)
VARCHAR2 (10 Byte)
VARCHAR2 (100 Byte)
VARCHAR2 (60 Byte)
VARCHAR2 (13 Byte)
VARCHAR2 (13 Byte)
NUMBER
NUMBER
VARCHAR2 (11 Byte)
NUMBER
NUMBER
NUMBER

NNZ_INITIAL_APP_CLAIM_CNT
INITIAL_APP_PAT_PAY
INITIAL_PLAN_APP_PLAN_PAY
INTERIM_APP_CLAIM_CNT
INTERIM_REJ_CLAIM_CNT
INTERIM_REV_CLAIM_CNT
INTERIM_PLAN_APP_CLAIM_CNT
NN_INTERIM_APP_CLAIM_CNT
NNZ_INTERIM_APP_CLAIM_CNT
NN_INTERIM_REV_CLAIM_CNT
NNZ_INTERIM_REV_CLAIM_CNT
NN_INTRM_PLN_APP_CLM_CNT
NNZ_INTRM_PLN_APP_CLM_CNT
INTERIM_APP_PAT_PAY
INTERIM_REV_PAT_PAY
INTERIM_PLAN_APP_PAT_PAY
INTERIM_PLAN_APP_PLAN_PAY
FINAL_APP_CLAIM_CNT
FINAL_REJ_CLAIM_CNT
FINAL_REV_CLAIM_CNT
FINAL_PLAN_APP_CLAIM_CNT
NN_FINAL_APP_CLAIM_CNT
NNZ_FINAL_APP_CLAIM_CNT
NN_FINAL_REV_CLAIM_CNT
NNZ_FINAL_REV_CLAIM_CNT
NN_FINAL_PLN_APP_CLM_CNT
NNZ_FINAL_PLN_APP_CLM_CNT
FINAL_APP_PAT_PAY
FINAL_REV_PAT_PAY
FINAL_PLAN_APP_PAT_PAY
FINAL_PLAN_APP_PLAN_PAY
PRACTITIONER_ID
PHYSICIAN_LAST_NAME
PHYSICIAN_FIRST_NAME
PHYSICIAN_ADDRESS
PHYSICIAN_CITY
PHYSICIAN_STATE_CODE
PHYSICIAN_ZIP_CODE
PHYSICIAN_SPECIALTY
AMA_NO_CONTACT
AMA_PDRP_FLAG
AMA_PDRP_DATE
NPI

81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
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NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER
NUMBER (18)
VARCHAR2 (60 Byte)
VARCHAR2 (25 Byte)
VARCHAR2 (100 Byte)
VARCHAR2 (28 Byte)
CHAR (2 Byte)
CHAR (5 Byte)
VARCHAR2 (75 Byte)
CHAR (1 Byte)
CHAR (1 Byte)
DATE ('DD-MON-YY')
VARCHAR2 (10 Byte)
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